this post was submitted on 11 Aug 2023
568 points (94.4% liked)
Asklemmy
43936 readers
677 users here now
A loosely moderated place to ask open-ended questions
If your post meets the following criteria, it's welcome here!
- Open-ended question
- Not offensive: at this point, we do not have the bandwidth to moderate overtly political discussions. Assume best intent and be excellent to each other.
- Not regarding using or support for Lemmy: context, see the list of support communities and tools for finding communities below
- Not ad nauseam inducing: please make sure it is a question that would be new to most members
- An actual topic of discussion
Looking for support?
Looking for a community?
- Lemmyverse: community search
- sub.rehab: maps old subreddits to fediverse options, marks official as such
- !lemmy411@lemmy.ca: a community for finding communities
~Icon~ ~by~ ~@Double_A@discuss.tchncs.de~
founded 5 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
Yeah with pharma in particular you need that initial profitability, as you say.
Additionally...
This doesn't really make sense. Shenzen company's might have copied products developed by other companies, but surely you still need another company to invest the R & D initially in order to have something to copy.
Consumer products don't "evolve". Developing and producing are two different processes. If there's no IP then there's only an incentive to produce things, and no incentive to develop them. I think this is especially true of pharmaceuticals given that there's no incremental / evolutionary pathway to discovering new drugs and the costs of conducting trials et cetera is preclusive.